A Phase 1 Dose-Escalation Study of XL147 (SAR245408) in Combination With Erlotinib in Subjects With Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 01 Mar 2015
At a glance
- Drugs Erlotinib; Pilaralisib
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 22 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Sep 2011 Planned end date changed from 1 Dec 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.
- 16 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.